Ascentage Pharma Group International (AAPGV)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ascentage Pharma Group International (AAPGV) with AI Score 46/100 (Weak). Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Ascentage Pharma Group International (AAPGV) Healthcare & Pipeline Overview
Ascentage Pharma Group International is a clinical-stage biotechnology firm specializing in innovative therapies for cancers, HBV, and age-related ailments, primarily in Mainland China. Their pipeline includes HQP1351, a BCR-ABL inhibitor, and other novel treatments targeting critical pathways in hematologic malignancies and solid tumors, positioning them in the competitive biotechnology landscape.
Investment Thesis
Ascentage Pharma presents a compelling investment case based on its innovative pipeline of clinical-stage drug candidates targeting significant unmet needs in oncology and related diseases. The company's lead asset, HQP1351, addresses BCR-ABL mutants, including the challenging T315I mutation. Further value drivers include APG-2575, APG-115, and APG-1252, each targeting critical pathways in cancer development. Key catalysts include clinical trial readouts for these assets, potential regulatory approvals, and strategic partnerships. However, the company's negative profit margin of -296.8% and reliance on future product commercialization pose significant risks. Success hinges on positive clinical data, regulatory success, and effective market access strategies.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.13 billion reflects the company's current valuation in the biotechnology sector.
- Negative P/E ratio of -12.42 indicates that the company is currently not profitable.
- Gross margin of 90.9% suggests strong potential profitability upon commercialization of its drug candidates.
- Profit margin of -296.8% highlights the significant R&D expenses associated with clinical-stage biotechnology companies.
- Beta of 1.10 indicates that the stock is slightly more volatile than the market.
Competitors & Peers
Strengths
- Innovative pipeline of clinical-stage drug candidates.
- Proprietary technology platform for small molecule inhibitor design.
- Strong intellectual property protection.
- Experienced management team with expertise in drug development.
Weaknesses
- Negative profitability and reliance on future product commercialization.
- High R&D expenses associated with clinical-stage development.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Limited commercial infrastructure.
Catalysts
- Upcoming: Clinical trial readouts for HQP1351 in chronic myeloid leukemia (CML).
- Upcoming: Regulatory submissions for APG-2575 in hematologic malignancies.
- Ongoing: Expansion of strategic partnerships and collaborations.
- Ongoing: Advancement of APG-115 into later-stage clinical trials.
- Ongoing: Development of new drug candidates targeting age-related diseases.
Risks
- Potential: Clinical trial failures and regulatory setbacks.
- Potential: Competition from established pharmaceutical companies and emerging biotech firms.
- Ongoing: High R&D expenses and negative profitability.
- Ongoing: Dependence on successful product commercialization.
- Potential: Patent expirations and generic competition.
Growth Opportunities
- Expansion of HQP1351: HQP1351, Ascentage's lead product candidate, presents a significant growth opportunity by targeting BCR-ABL mutants, including those with the T315I mutation. The market for targeted therapies in chronic myeloid leukemia (CML) is substantial, and HQP1351's potential to overcome resistance to existing treatments positions it for significant market penetration. Successful clinical trials and regulatory approvals in key markets, including China and the United States, could drive substantial revenue growth over the next 3-5 years.
- Development of APG-2575: APG-2575, an orally administered Bcl-2 selective inhibitor, represents a promising growth avenue in hematologic malignancies and solid tumors. The Bcl-2 inhibitor market is expanding, with increasing recognition of its role in cancer cell survival. Positive clinical data demonstrating efficacy and safety could lead to regulatory approvals and commercialization within the next 4-6 years, capturing a share of the growing market for targeted cancer therapies.
- Advancement of APG-115: APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions, offers a growth opportunity in treating solid tumors and hematological malignancies. The MDM2-p53 pathway is a critical target in cancer therapy, and APG-115's potential to restore p53 function could lead to significant clinical benefits. Successful clinical trials and regulatory approvals could drive commercialization within the next 5-7 years, addressing a substantial unmet need in cancer treatment.
- Strategic Partnerships and Collaborations: Ascentage Pharma can leverage strategic partnerships and collaborations with biotechnology and pharmaceutical companies to accelerate the development and commercialization of its drug candidates. Collaborations can provide access to additional funding, expertise, and market access, enhancing the company's growth prospects. Successful partnerships could lead to revenue-sharing agreements and milestone payments, contributing to long-term growth and profitability.
- Expansion into New Therapeutic Areas: Ascentage Pharma can explore opportunities to expand its pipeline into new therapeutic areas beyond oncology, such as age-related diseases and chronic HBV infection. These areas represent significant unmet medical needs and potential growth markets. By leveraging its expertise in drug discovery and development, Ascentage can diversify its pipeline and create new revenue streams over the long term. This strategic diversification could mitigate risks associated with reliance on a single therapeutic area.
Opportunities
- Expansion into new therapeutic areas and indications.
- Strategic partnerships and collaborations with pharmaceutical companies.
- Accelerated regulatory pathways for orphan drugs and breakthrough therapies.
- Growing market for targeted cancer therapies.
Threats
- Competition from established pharmaceutical companies and emerging biotech firms.
- Clinical trial failures and regulatory setbacks.
- Patent expirations and generic competition.
- Economic downturns and healthcare reforms.
Competitive Advantages
- Proprietary drug candidates with patent protection.
- Expertise in small molecule inhibitor design and development.
- Established clinical development capabilities.
- Strategic collaborations with biotechnology and pharmaceutical companies.
About AAPGV
Founded in 2009 and headquartered in Suzhou, China, Ascentage Pharma Group International is a clinical-stage biotechnology company dedicated to discovering, developing, and commercializing innovative therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases. The company's lead product candidate is HQP1351, a BCR-ABL inhibitor designed to target BCR-ABL1 mutants, including those with the T315I mutation, which often confers resistance to existing treatments. Ascentage Pharma is also developing a diverse pipeline of drug candidates, including APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors, and APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies. Furthermore, the company is advancing APG-1252, a small molecule drug designed to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. Ascentage Pharma's commitment extends to medical research and development, clinical development, and clinical trial operations, with collaborations established with biotechnology and pharmaceutical companies, as well as research institutions. This comprehensive approach underscores their mission to address unmet medical needs and improve patient outcomes.
What They Do
- Develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases.
- Focuses on small molecule inhibitors targeting key pathways in cancer development.
- Conducts medical research and development to identify novel drug candidates.
- Manages clinical development programs to evaluate the safety and efficacy of its therapies.
- Operates clinical trials to generate data for regulatory submissions.
- Engages in venture capital investment to support innovation in the biotechnology sector.
- Provides rental services and science and technology promotion services.
Business Model
- Develops and patents novel drug candidates targeting specific disease pathways.
- Conducts preclinical and clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approvals from agencies such as the FDA and EMA.
- Commercializes approved drugs through its own sales force or through partnerships with other pharmaceutical companies.
Industry Context
Ascentage Pharma operates within the dynamic and competitive biotechnology industry, characterized by rapid innovation, stringent regulatory requirements, and high capital intensity. The global oncology market, a primary focus for Ascentage, is projected to reach hundreds of billions of dollars by 2026, driven by an aging population and advancements in personalized medicine. Ascentage competes with established pharmaceutical giants and emerging biotech firms, including ATYR Pharma, BCYP, CYT, DBTX, and GRAY, all vying for market share in targeted therapies. Success in this landscape requires robust clinical data, strategic partnerships, and efficient commercialization strategies.
Key Customers
- Patients suffering from cancers, chronic hepatitis B virus (HBV), and age-related diseases.
- Hospitals and clinics that administer Ascentage Pharma's therapies.
- Pharmaceutical companies that may partner with Ascentage Pharma to develop and commercialize its drugs.
Financials
Chart & Info
Ascentage Pharma Group International (AAPGV) stock price: Price data unavailable
Latest News
No recent news available for AAPGV.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AAPGV.
Price Targets
Wall Street price target analysis for AAPGV.
MoonshotScore
What does this score mean?
The MoonshotScore rates AAPGV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Dajun Yang
CEO
Dajun Yang is the CEO of Ascentage Pharma Group International. His background includes extensive experience in the pharmaceutical and biotechnology industries. He has a proven track record in drug development, clinical trials, and commercialization. Yang's expertise spans various therapeutic areas, including oncology, virology, and age-related diseases. He has held leadership positions in several multinational pharmaceutical companies, contributing to the development and launch of multiple successful products. His educational background includes advanced degrees in chemistry and pharmacology.
Track Record: Under Dajun Yang's leadership, Ascentage Pharma has advanced its pipeline of drug candidates through clinical development, achieving key milestones in regulatory submissions and strategic partnerships. He has overseen the expansion of the company's research and development capabilities, strengthening its position in the biotechnology sector. Yang has also played a crucial role in securing funding and investments to support the company's growth initiatives.
AAPGV OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ascentage Pharma Group International may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, minimal assets, or are undergoing financial distress. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and information transparency compared to exchanges like the NYSE or NASDAQ. Investors should exercise extreme caution and conduct thorough due diligence before considering an investment in AAPGV.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited information disclosure due to lower regulatory requirements.
- Higher potential for fraud and manipulation compared to listed exchanges.
- Greater price volatility and illiquidity.
- Increased risk of delisting or trading suspensions.
- Potential for limited access to company management and information.
- Verify the company's legal status and registration.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the company's capital structure and ownership.
- Determine the level of trading volume and liquidity.
- Consult with a qualified financial advisor.
- Established partnerships with reputable biotechnology or pharmaceutical companies.
- Positive clinical trial results for its drug candidates.
- Experienced management team with a proven track record.
- Patent protection for its key technologies.
- Independent audits of its financial statements (if available).
What Investors Ask About Ascentage Pharma Group International (AAPGV)
What does Ascentage Pharma Group International do?
Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing innovative therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases. The company's primary focus is on small molecule inhibitors that target key pathways involved in disease development. Their lead product candidate, HQP1351, is a BCR-ABL inhibitor designed to overcome resistance to existing treatments in chronic myeloid leukemia (CML). Ascentage Pharma is also developing a pipeline of other drug candidates targeting hematologic malignancies and solid tumors, positioning them as a key player in the biotechnology sector.
What do analysts say about AAPGV stock?
Analyst coverage of AAPGV is pending, reflecting the company's status as an emerging player in the biotechnology sector. Key valuation metrics, such as price-to-earnings (P/E) ratio and price-to-sales (P/S) ratio, are currently less relevant due to the company's negative profitability. Growth considerations center on the successful development and commercialization of its drug candidates, particularly HQP1351. Analyst sentiment will likely depend on clinical trial outcomes, regulatory approvals, and strategic partnerships. Investors should monitor analyst reports for updates on AAPGV's prospects.
What are the main risks for AAPGV?
Ascentage Pharma faces several key risks inherent to the biotechnology industry. Clinical trial failures represent a significant risk, as negative results could delay or halt the development of its drug candidates. Regulatory setbacks, such as rejection of regulatory submissions, could also impede progress. Competition from established pharmaceutical companies and emerging biotech firms poses a threat to market share. Additionally, the company's high R&D expenses and negative profitability create financial risks, requiring continued access to capital to fund its operations.
What are the key factors to evaluate for AAPGV?
Ascentage Pharma Group International (AAPGV) currently holds an AI score of 46/100, indicating low score. Key strength: Innovative pipeline of clinical-stage drug candidates.. Primary risk to monitor: Potential: Clinical trial failures and regulatory setbacks.. This is not financial advice.
How frequently does AAPGV data refresh on this page?
AAPGV prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AAPGV's recent stock price performance?
Recent price movement in Ascentage Pharma Group International (AAPGV) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative pipeline of clinical-stage drug candidates.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AAPGV overvalued or undervalued right now?
Determining whether Ascentage Pharma Group International (AAPGV) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AAPGV?
Before investing in Ascentage Pharma Group International (AAPGV), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- AI analysis pending for AAPGV.